The Whitrod family launched Genetic Cures for Kids in the hopes of finding a treatment for their daughter with hereditary ...

The firm will use the funds to conduct a Phase I/II trial of an adoptive cell therapy designed to activate T regulatory cells against cancer.

The firm will use the money to advance its lead FAP-targeting radioligand candidate into clinical development.

The firm is hoping to show that the RNAi drug can treat HoFH by reducing production of ANGPTL3, which regulates lipid and lipoprotein metabolism.